These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37757668)

  • 1. Acetate mitigates cardiac mitochondrial dysfunction in experimental model of polycystic ovarian syndrome by modulating GPCR41/43 and PROKR1.
    Areloegbe SE; Olaniyi KS
    Biochem Biophys Res Commun; 2023 Nov; 681():62-72. PubMed ID: 37757668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of PCSK9/NF-kB-dependent pathways by acetate ameliorates cardiac inflammation in a rat model of polycystic ovarian syndrome.
    Olaniyi KS; Areloegbe SE
    Life Sci; 2022 Jul; 300():120560. PubMed ID: 35452635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Butyrate alleviates renal inflammation and fibrosis in a rat model of polycystic ovarian syndrome by suppression of SDF-1.
    Bashir AM; Olaniyi KS
    BMC Pharmacol Toxicol; 2023 Oct; 24(1):48. PubMed ID: 37789355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetate circumvents impaired metabolic switch in skeletal muscle of letrozole-induced PCOS rat model by suppression of PDK4/NLRP3.
    Olaniyi KS; Areloegbe SE
    Nutrition; 2023 Mar; 107():111914. PubMed ID: 36521396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetate: A therapeutic candidate against renal disorder in a rat model of polycystic ovarian syndrome.
    Olaniyi KS; Areloegbe SE
    J Steroid Biochem Mol Biol; 2023 Jan; 225():106179. PubMed ID: 36150640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short chain fatty acid, acetate restores ovarian function in experimentally induced PCOS rat model.
    Olaniyi KS; Bashir AM; Areloegbe SE; Sabinari IW; Akintayo CO; Oniyide AA; Aturamu A
    PLoS One; 2022; 17(7):e0272124. PubMed ID: 35881588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetate restores hypothalamic-adipose kisspeptin status in a rat model of PCOS by suppression of NLRP3 immunoreactivity.
    Olaniyi KS; Areloegbe SE; Oyeleke MB
    Endocrine; 2022 Dec; 78(3):628-640. PubMed ID: 36114434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective Role of Acetate Against Depressive-Like Behaviour Associated with Letrozole-Induced PCOS Rat Model: Involvement of HDAC2 and DNA Methylation.
    Wolugbom JA; Areloegbe SE; Olaniyi KS
    Mol Neurobiol; 2023 Jan; 60(1):355-368. PubMed ID: 36269541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model.
    Areloegbe SE; Peter MU; Oyeleke MB; Olaniyi KS
    BMC Endocr Disord; 2022 Sep; 22(1):224. PubMed ID: 36071485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of sodium selenite in letrozole induced polycystic ovary syndrome rat model: Targeting mitochondrial approach (selenium in PCOS).
    Atef MM; Abd-Ellatif RN; Emam MN; Abo El Gheit RE; Amer AI; Hafez YM
    Arch Biochem Biophys; 2019 Aug; 671():245-254. PubMed ID: 31251923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alleviation of adipose-hepatic glycolipid dysregulation by acetate in experimental PCOS model is associated with NF-κB/NLRP3 repression.
    Olaniyi K; Areloegbe S
    Can J Physiol Pharmacol; 2023 Dec; 101(12):630-641. PubMed ID: 37590975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose spironolactone abates cardio-renal disorder by reduction of BAX/inflammasome expression in experimentally induced polycystic ovarian syndrome rat model.
    Peter MU; Areloegbe SE; Akintayo CO; Oniyide AA; Aturamu A; Olaniyi KS
    Can J Physiol Pharmacol; 2022 Sep; 100(9):890-902. PubMed ID: 35771488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS.
    Olaniyi KS; Oniyide AA; Adeyanju OA; Ojulari LS; Omoaghe AO; Olaiya OE
    Toxicol Appl Pharmacol; 2021 Jan; 411():115381. PubMed ID: 33359182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel insights into the synergistic effects of selenium nanoparticles and metformin treatment of letrozole - induced polycystic ovarian syndrome: targeting PI3K/Akt signalling pathway, redox status and mitochondrial dysfunction in ovarian tissue.
    Rabah HM; Mohamed DA; Mariah RA; Abd El-Khalik SR; Khattab HA; AbuoHashish NA; Abdelsattar AM; Raslan MA; Farghal EE; Eltokhy AK
    Redox Rep; 2023 Dec; 28(1):2160569. PubMed ID: 36661246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone reversed hepato-ovarian triglyceride accumulation caused by letrozole-induced polycystic ovarian syndrome: tissue uric acid-a familiar foe.
    Adeyanju OA; Falodun TO; Michael OS; Soetan OA; Oyewole AL; Agbana RD
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Jun; 393(6):1055-1066. PubMed ID: 31925474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ameliorating effects of Guizhi Fuling Wan combined with rosiglitazone in a rat ovarian model of polycystic ovary syndrome by the PI3K/AKT/NF-κB and Nrf2/HO-1 pathways.
    Ye Y; Zhou W; Ren Y; Lu J; Chen A; Jin R; Xuan F
    Gynecol Endocrinol; 2023 Dec; 39(1):2254848. PubMed ID: 37706434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of berberine on LPS /NF-κB and MAPK signaling pathways in PCOS model rats].
    Zhao FQ; Zhao Y; Liu JY; Gou YJ; Yang YQ
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2022 Mar; 38(2):181-186. PubMed ID: 36031579
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic Potential of Selenium Nanoparticles on Letrozole-Induced Polycystic Ovarian Syndrome in Female Wistar Rats.
    Butt MA; Shafique HM; Mustafa M; Moghul NB; Munir A; Shamas U; Tabassum S; Kiyani MM
    Biol Trace Elem Res; 2023 Nov; 201(11):5213-5229. PubMed ID: 36694071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model.
    Karateke A; Dokuyucu R; Dogan H; Ozgur T; Tas ZA; Tutuk O; Agturk G; Tumer C
    Med Princ Pract; 2018; 27(6):515-522. PubMed ID: 30293079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partially purified non-polar phytocomponents from Aloe barbadensis Mill. gel restores metabolic and reproductive comorbidities in letrozole-induced polycystic ovary syndrome rodent model- an "in-vivo" study.
    Dey A; Dhadhal S; Maharjan R; Nagar PS; Nampoothiri L
    J Ethnopharmacol; 2022 Jun; 291():115161. PubMed ID: 35271948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.